Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06909500 · ClinicalTrials.gov registry record · NA
A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 1,178
- Enrollment target
NCT06909500: Recruiting NA study, sponsored by Fred Hutchinson Cancer Center.
NCT06909500 is a NA study that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 1,178 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06909500, a NA study, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,178 participants
- Enrollment target
Study Summary
This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of e-cigarette use by young adults requires effective and accessible treatments to support current users to quit. Research shows this group prefers and benefits from newer methods of treatment delivery such as digital interventions. ACT on Vaping is a digital therapeutic intended to deliver behavioral therapy to young adults who vape to motivate and support abstinence from all nicotine and tobacco products. The app contains sessions that promote awareness of cues that trigger tobacco use and teach skills for responding to these triggers in a way that is tailored for the participant's readiness to quit. Receiving access to the ACT on Vaping app may be effective in helping young adults quit vaping.
Primary Outcome
Biochemically confirmed 30-day abstinence from all nicotine and tobacco (excluding Food and Drug Administration \[FDA\]-approved pharmacotherapies). Will be assessed in each individual and summarized within each group as a proportion.
Interventions
- OTHER Survey Administration
- OTHER Text Message
- BEHAVIORAL Smartphone app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,178 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2027-11-15 |
| Phase | NA |
What NCT06909500 shows while recruiting
NCT06909500 is an interventional study that assigns participants to a tested intervention. Its 1,178 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 3 interventions - of which Survey Administration is the first listed.
NCT06909500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06909500 about?
NCT06909500 is a clinical study titled "A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users". This clinical trial evaluates a smartphone application (app) called Acceptance and Commitment Therapy (ACT) on Vaping for helping young adults quit using electronic cigarettes (e-cigarettes). E-cigarettes pose numerous risks, particularly to youth and young adults. Addressing the high prevalence of ...
What is the current status of trial NCT06909500?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,178 participants. The study started on 2026-07-15. Estimated completion is 2027-11-15.
What interventions are being tested in trial NCT06909500?
The interventions under investigation include: Survey Administration (OTHER), Text Message (OTHER), Smartphone app (BEHAVIORAL).
Who is sponsoring clinical trial NCT06909500?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06909500's enrollment target sits among peer trials
1,178 89th of 2000 higher than 1,911 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI